Erschienen in:
30.05.2018 | Breast Oncology
Optimizing Surgical Management of the Axilla After Neoadjuvant Chemotherapy: An Evolving Story
verfasst von:
Eleftherios P. Mamounas, MD, MPH, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2018
Einloggen, um Zugang zu erhalten
Excerpt
For patients with operable breast cancer and clinically negative axilla who undergo surgery first, sentinel lymph node biopsy (SLNB) has been established as the gold standard for pathologic evaluation of the axilla. When the SLN is negative, no further surgery in the axilla is required. Traditionally, intraoperative frozen section (FS) was used to assess SLN status. However, randomized clinical trials have shown that selected patients with clinically negative axilla and limited SLN involvement can be spared from completion axillary lymph node dissection (ALND).
1,
2 Therefore, intraoperative FS currently is reserved primarily for patients who do not meet criteria for inclusion or were underrepresented in those trials (e.g., patients undergoing mastectomy and those who have received neoadjuvant chemotherapy [NAC] before the SLNB). …
